A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).

Andrea Cercek,Nancy E. Kemeny,Thomas Boerner,Benjamin R. Tan,Joanne F. Chou,Mithat Gonen,Taryn Mary Boucher,Haley Hauser,Richard K. G. Do,Maeve Aine Lowery,Peter Kingham,Michael I. D’Angelica,Jeffrey A. Drebin,Peter J. Allen,Neeta Vachharajani,Maria Majella Doyle,Ryan C. Fields,William G. Hawkins,William C. Chapman,William R. Jarnagin

A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).

2018

4092Background: Despite advances in systemic therapy for unresectable ICC, median survival remains less than 12 months (mo). HAI FUDR alone and combination systemic therapy both have activity in th...

Keywords:

Dexamethasone
Gastroenterology
Pathology
Phases of clinical research
GemOx
Hepatic arterial infusion
Oxaliplatin
Gemcitabine
Floxuridine
Intrahepatic Cholangiocarcinoma
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations